There will be 6 months of follow up including 3 medical visits for each patients:
* M0 (medical visit for inclusion)
* follow up between M0 - M3
* M3 (medical visit at 3 months after inclusion)
* follow up between M3 - M6
* M6 (medical visit at 6 months after inclusion)
At the inclusion visit (M0), after the verification of inclusion and non-inclusion criteria, the following information will be collected:
* Socio-demographical data : age, sex, level of education (primary, secondary, college, university), occupational category (INSEE in 6 categories)
* Items of the ACR 1987 and ACR/EULAR 2010;
* Length of the RA
* Erosive or not (presence Yes / no)
* IgM rheumatoid factor (presence Yes / No)
* Anti CCP antbodies (presence Yes / No)
During follow-up visits (M3 and M6), the elements collected are:
1. by the study technician (TEC)
* the inflammatory activity index, evaluated by patient (RAPID-3);
* the functional limitations index (HAQ);
* the PASS questionnaire;
* the OM-RA-FLARE questionnaire;
* the FLARE questionnaire.
2. by the doctor :
* elements of DAS 28, this includes a blood test that will be done in the city or in the hospital ;
* the doctor's decision at the end of the consultation, in terms of :
* DMRADs: continuing the treatment, decreasing or increasing the dose, changing it due to its ineffectiveness, changing it due to patients' intolerance.
* Symptomatic treatments: continuing corticosteroids, increase the dose of corticosteroids, corticosteroid infiltration.
